Subscribe To

Price Alert Latest News Economic Calendar News

ALLO / SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO

New York, New York--(Newsfile Corp. - October 8, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.The investigation concerns whether Allogene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining... Read More

Demo Live Account See Partner Details

Content Topics

White

Mountains

Insurance

Group

Ltd

Wtm

Shareholder

Alert

Pomerantz

Investigates

Claims

Behalf

Investors

Allogene

Therapeutics

Stock

ALLO

Posted: Oct 8 2021, 22:08

Author Name: Newsfile Corp

ALLO News

By Seeking Alpha
November 2, 2023

Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Christine Cassiano – Ch

By GlobeNewsWire
October 30, 2023

Allogene Therapeutics Announces Participation in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pion

By The Motley Fool
October 10, 2023

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate

By Seeking Alpha
August 2, 2023

Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief

By Zacks Investment Research
August 2, 2023

Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares t

By Seeking Alpha
July 26, 2023

Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before

Allogene Therapeutics, Inc. is the leading developer of allogeneic CAR-T. There was a time when its logic appealed to me. Lately, however, I have incr

By GlobeNewsWire
July 26, 2023

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pion

By Zacks Investment Research
May 26, 2023

Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High?

The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 210.2% upside in the stock. While this highly sought-after metric has

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.